The Impact of Artificial Intelligence in the Odyssey of Rare Diseases

Author:

Visibelli Anna1ORCID,Roncaglia Bianca1,Spiga Ottavia123ORCID,Santucci Annalisa123ORCID

Affiliation:

1. Department of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy

2. Competence Center ARTES 4.0, 53100 Siena, Italy

3. SienabioACTIVE—SbA, 53100 Siena, Italy

Abstract

Emerging machine learning (ML) technologies have the potential to significantly improve the research and treatment of rare diseases, which constitute a vast set of diseases that affect a small proportion of the total population. Artificial Intelligence (AI) algorithms can help to quickly identify patterns and associations that would be difficult or impossible for human analysts to detect. Predictive modeling techniques, such as deep learning, have been used to forecast the progression of rare diseases, enabling the development of more targeted treatments. Moreover, AI has also shown promise in the field of drug development for rare diseases with the identification of subpopulations of patients who may be most likely to respond to a particular drug. This review aims to highlight the achievements of AI algorithms in the study of rare diseases in the past decade and advise researchers on which methods have proven to be most effective. The review will focus on specific rare diseases, as defined by a prevalence rate that does not exceed 1–9/100,000 on Orphanet, and will examine which AI methods have been most successful in their study. We believe this review can guide clinicians and researchers in the successful application of ML in rare diseases.

Publisher

MDPI AG

Subject

General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)

Reference103 articles.

1. Challenges and Opportunities in The Treatment of Rare Diseases;Vickers;Drug Discov. World,2013

2. Drugs for exceptionally rare diseases: Do they deserve special status for funding?;Hughes;QJM Int. J. Med.,2005

3. Estimating cumulative point prevalence of rare diseases: Analysis of the Orphanet database;Lambert;Eur. J. Hum. Genet.,2020

4. European Union (2022, November 18). Regulation (EC) N°141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32000R0141.

5. National Institute of Health (2022, December 14). Public Law 97–414 97th Congress, Available online: https://www.govinfo.gov/content/pkg/STATUTE-96/pdf/STATUTE-96-Pg2049.pdf.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3